Tumor Necrosis Factor Inhibitors

Compounds or agents that bind to and inhibit the synthesis or activity of TUMOR NECROSIS FACTOR-alpha. Such agents are used to treat inflammatory bowel diseases and other inflammatory diseases.

Also Known As:

TNF Antagonists; TNF Blockers; TNF Inhibitors; Tumor Necrosis Factor Antagonists; Tumor Necrosis Factor Blockers; Tumor Necrosis Factor-a (TNF-a) Antagonists; Tumor Necrosis Factor-a (TNF-a) Blockers; Tumor Necrosis Factor-a (TNF-a) Inhibitors; Antagonist, TNF; Antagonists, TNF; Blocker, TNF; Blockers, TNF; Inhibitor, TNF; Inhibitors, TNF; TNF Antagonist; TNF Blocker; TNF Inhibitor; Tumor Necrosis Factor Antagonist; Tumor Necrosis Factor Blocker; Tumor Necrosis Factor Inhibitor; Tumor Necrosis Factor-a (TNF-a) Antagonist; Tumor Necrosis Factor-a (TNF-a) Blocker; Tumor Necrosis Factor-a (TNF-a) Inhibitor

Networked: 3105 relevant articles (384 outcomes, 513 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Therapeutic Uses: 47080
    - Anti-Inflammatory Agents: 4247
      - Tumor Necrosis Factor Inhibitors: 3105

Experts

1.	Sandborn, William J: 32 articles (01/2022 - 01/2004)
2.	Curtis, Jeffrey R: 29 articles (01/2022 - 10/2008)
3.	Askling, Johan: 27 articles (11/2022 - 05/2004)
4.	Sieper, Joachim: 26 articles (01/2022 - 07/2003)
5.	Combe, Bernard: 26 articles (09/2021 - 11/2004)
6.	Emery, Paul: 24 articles (11/2021 - 01/2003)
7.	Deodhar, Atul: 22 articles (11/2022 - 06/2014)
8.	Carmona, Loreto: 22 articles (10/2021 - 08/2003)
9.	Feagan, Brian G: 22 articles (02/2021 - 12/2011)
10.	Mariette, Xavier: 21 articles (01/2022 - 12/2006)

Related Diseases

1.	Rheumatoid Arthritis 05/01/2012 - "Although TNF inhibitors have dramatically improved the outcome of patients with rheumatoid arthritis, 30-40% of patients do not respond well to them and treatment needs to be changed. " 11/20/2023 - "To determine the prevalence of sustained remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) after discontinuation of tumor necrosis factor inhibitors (TNFi), separately in induction treatment and maintenance treatment studies, and to identify predictors of successful discontinuation. " 01/01/2015 - "Three cases of previous smokers with rheumatoid arthritis who did not respond to tumor necrosis factor inhibitors were treated successfully with an anti-interleukin-6 receptor antibody." 11/20/2023 - "Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review." 05/01/2015 - "Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study."
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 02/01/2018 - "The use of TNF inhibitors in psoriasis showed a significant reduction in the risk of MI compared with topical agents and a non-significant reduction compared with MTX. " 05/15/2013 - "Use of TNF inhibitors for psoriasis was associated with a significant reduction in MI risk and incident rate compared with treatment with topical agents. " 11/01/2012 - "CONCLUSIONS Use of TNF inhibitors for psoriasis was associated with a significant reduction in MI risk and incident rate compared with treatment with topical agents. " 01/01/2023 - "The efficacy of tumor necrosis factor inhibitors (TNFi) for the treatment of psoriasis is well established, but patients may develop psoriasis for the first time while on TNFi as a paradoxical effect. " 08/25/2023 - "Tumor necrosis factor inhibitors were the first class of biologics approved and at that time greatly improved psoriasis treatment. "
3.	Psoriatic Arthritis 05/01/2009 - "Tumor necrosis factor inhibitors are an effective treatment for psoriatic arthritis, but no single agent is effective in all patients. " 06/14/2023 - "Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries." 01/01/2019 - "Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor." 07/01/2016 - "Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis." 01/01/2016 - "Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors."
4.	Necrosis 02/01/2017 - "We used data from two pivotal trials of tumour necrosis factor (TNF) inhibitors in PsA (IMPACT II and GO-REVEAL) and identified patients in DAPSA remission (REM, ≤4), and low, moderate or high disease activity (LDA, ≤14; MDA, ≤28; HDA, >28) at 6 months. " 10/01/2010 - "The tumour necrosis factor (TNF) antagonists have significantly improved quality of life and functional status in patients with spondyloarthritis (SpA). " 03/01/2023 - "Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate-to-severe HS. " 01/21/2019 - "Biologic tumour necrosis factor (TNF)-inhibitors are effective in the treatment of PsA. " 04/01/2013 - "Tumour necrosis factor (TNF) blockers have been demonstrated to be effective in the treatment of systemic and ocular inflammatory diseases. "
5.	Ankylosing Spondylitis 05/31/2012 - "The ASAS criteria evolved from the idea that the earlier the recognition of patients with ankylosing spondylitis, the better the efficacy of tumor necrosis factor blockers. " 07/01/2010 - "It could be shown that TNF-blockers are at least as effective in patients with axial nonradiographic spondyloarthritis when compared with established ankylosing spondylitis and that TNF-blockers are even more effective when used earlier in the course of the disease and in younger age. " 11/01/2008 - "In light of the impressive efficacy of tumor necrosis factor blockers in the treatment of ankylosing spondylitis, particularly in patients with short disease duration, defining outcome parameters to monitor the structural damage of the disease has become more pertinent. " 12/04/2018 - "Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors." 01/01/2019 - "Objective: This prospective observational study investigated the efficacy of tumor necrosis factor inhibitors (TNFis) on disease activity, physical functionality, and mobility in patients with ankylosing spondylitis (AS) in a real-world setting. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Etanercept (Enbrel)
3.	Infliximab (Remicade)
4.	Methotrexate (Mexate)
5.	Adalimumab (Humira)
6.	Tumor Necrosis Factor Inhibitors
7.	tocilizumab (atlizumab)
8.	Antirheumatic Agents (DMARD)
9.	Abatacept (Orencia)
10.	golimumab

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy
3.	Drug Tapering
4.	Injections
5.	Aftercare (After-Treatment)